Active ingredientMitapivatCat. No. P-M144-001CAS 1260075-17-9Family · Pharmaceutical analytical standards
Mitapivat
The first oral pyruvate kinase activator, approved in 2022 in the United States and the European Union for haemolytic anaemia due to pyruvate kinase deficiency and, in 2025, in the United States for anaemia in thalassaemia. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?Instead of blocking an enzyme, as many drugs do, it activates one: by boosting pyruvate kinase it raises ATP, the energy reserve of red blood cells, and lowers 2,3-DPG.
Go to the active ingredient →Active ingredientMitapivatCat. No. P-M144-001CAS 1260075-17-9
Isotopically labelledMitapivat Impurity 1-d8Cat. No. P-M144-002
Isotopically labelledMitapivat-d8Cat. No. P-M144-003
ImpurityMitapivat Desethylcyclopropane ImpurityCat. No. P-M144-004CAS 1260081-87-5No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.